$XBI $125.01 +0.32%
Pipeline Updates
$SRNE +2.3% Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors. source
$IBRX -1.6% ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date. source
$SRNE +2.3% FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain. source
$BLRX +8.8% BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization. source
$VERU +3.7% Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer. source
$SCYX +2.8% SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences. source
$ARDX -17.4% Ardelyx Provides Corporate Update Following Type A Meeting with FDA. source
$HZNP +1.4% New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD). source
$IMAB +2.4% I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China. source
$SELB +2.1% Selecta Biosciences to Present New Data for the ImmTOR™ platform at the ESGCT 28th Annual Congress. source
$VACC -1.4% Vaccitech to Present an Update on Its Chronic HBV Infection Immunotherapeutic Program at The World Vaccine Congress Europe. source
$VBI +0.7% VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open. source
$ANEB +4.9% Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose. source
$DYN +0.6% Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day. source
$VERA -0.4% Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual Meeting. source
$ABEO -1.9% Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses. source
$CLSD +0.9% Clearside Biomedical Delivers Podium and Poster Presentations at the American Society of Retina Specialists (ASRS) Annual Meeting. source
$NTLA -2.1% Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology. source
$TRVN 0.0% Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021. source
$ORTX +5.4% Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress. source
$TSHA +0.7% Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal Neuropathy (GAN) in Partnership with GeneDx as well as a Collaboration with Hereditary Neuropathy Foundation and Charcot-Marie-Tooth Association Centers of Excellence. source
$AVXL +2.5% Data Review by the Independent DSMB reported for Phase 2b/3 Trial of ANAVEX®2-73 for AD. source
$KYMR +1.4% Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit . source
$VRNA +7.3% Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021. source
$RVNC +12.9% Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021. source
$TSHA +0.7% Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-106 for the Treatment of Angelman Syndrome. source
$FIXX -5.6% Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU. source
Financial & Business Updates
$OSMT -2.0% Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering source
$OBSV -2.8% ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix. source
$BCYC +3.4% Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares. source
Posted by FS/JM
Comments